Israels Galmed to Acquire Colospan in Bid to Build $6B GI Medtech Platform
Israel's Galmed Pharmaceuticals is acquiring Colospan Ltd. to build a $6B GI medtech platform, leveraging Colospan's CE-marked bypass device.
Colospan Ltd.
Navigation
Israel's Galmed Pharmaceuticals is acquiring Colospan Ltd. to build a $6B GI medtech platform, leveraging Colospan's CE-marked bypass device.